| 货号 | 规格 | 价格 | 上海 | 北京 | 珠海 | 重庆 | 武汉 | 购买数量 |
|---|---|---|---|---|---|---|---|---|
V39274-1mg |
≥99% | ￥530.00 |
货期：3-5天 | - | - | - | - |
|
V39274-2mg |
≥99% | ￥780.00 |
货期：3-5天 | - | - | - | - |
|
V39274-5mg |
≥99% | ￥1210.00 |
货期：3-5天 | - | - | - | - |
|
V39274-10mg |
≥99% | ￥1840.00 |
货期：3-5天 | - | - | - | - |
|
V39274-25mg |
≥99% | ￥3040.00 |
货期：3-5天 | - | - | - | - |
|
V39274-50mg |
≥99% | ￥4260.00 |
货期：3-5天 | - | - | - | - |
|
V39274-100mg |
≥99% | ￥5680.00 |
货期：3-5天 | - | - | - | - |
|
V39274-500mg |
≥99% | ￥11200.00 |
货期：3-5天 | - | - | - | - |
|
| 体内研究： | AVE1625 (10 mg/kg orally once daily), combined with Olanzapine attenuates body weight gain, diminishing the enhanced food intake while maintaining increased energy expenditure and decreased motility. AVE1625 (1, 3, and 10 mg/kg ip), reverses abnormally persistent LI induced by MK-801 or neonatal nitric oxide synthase inhibition in rodents, and improves both working and episodic memory. |
||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 参考文献： | 1. Andreas W Herling, et al. CB1 receptor antagonist AVE1625 affects primarily metabolic parameters independently of reduced food intake in Wistar rats. Am J Physiol Endocrinol Metab. 2007 Sep;293(3):E826-32. 2. Michaela Liebig, et al. Profiling of energy metabolism in olanzapine-induced weight gain in rats and its prevention by the CB1-antagonist AVE1625. Obesity (Silver Spring). 2010 Oct;18(10):1952-8. 3. Mark D Black, et al. AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents. Psychopharmacology (Berl). 2011 May;215 |
||||||||||||||||||||
| 保存条件： | -20℃ | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京